Neuroendocrine tumors: Therapy with radiolabeled peptides Book Section

  


Authors: Bodei, L.; Jayaprakasam, V. S.; Kidd, M.; Gilardi, L.; Volterrani, D.; Paganelli, G.; Grana, C. M.; Modlin, I. M.
Editors: Volterrani, D.; Erba, P. A.; Strauss, H. W.; Mariani, G.; Larson, S. M.
Article/Chapter Title: Neuroendocrine tumors: Therapy with radiolabeled peptides
Abstract: Treatment of neuroendocrine tumors (NETs) is typically multidisciplinary and should be individualized according to the tumor histology, lesion extent, patient performance status, and symptoms. Surgery is the only potentially curative option. NET liver metastases are typically hypervascular, and chemoembolization or bland embolization of the hepatic artery, performed mechanically by microspheres or chemically with cytotoxic agents, can lead to significant necrosis. Medical therapy is directed at the control of symptoms and/or reducing tumor growth. Strategies range from the use of bioactive agents (somatostatin analogues or interferon) to conventional chemotherapy. PRRT uses radiolabeled somatostatin analogue peptides to treat unresectable or metastasized NETs. The therapeutic strategy of PRRT has been utilized for more than two decades and is accepted as an effective therapeutic modality in the treatment of inoperable or metastatic GEP, bronchopulmonary, and other NETs. PRRT with either 90Y-DOTATOC or 177Lu-DOTATATE is generally extremely well tolerated, with modest toxicity to the target organs, such as the kidneys and bone marrow. The chapter illustrates the efficacy and safety features of these compounds. © Springer Nature Switzerland AG 2022.
Keywords: therapy; neuroendocrine tumors; prrt; 177lu-dotatate; 90y-dotatoc
Book Title: Nuclear Oncology: From Pathophysiology to Clinical Applications. 3rd ed
ISBN: 978-3-031-05493-8
Publisher: Springer  
Publication Place: Cham, Switzerland
Date Published: 2022-01-01
Start Page: 1431
End Page: 1459
Language: English
DOI: 10.1007/978-3-031-05494-5_50
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85153836302&doi=10.1007%2f978-3-031-05494-5_50&partnerID=40&md5=0aa06eb12061bdebe18a04c28cfd934c
Notes: Book Chapter: 44, in the section "Part III - Radionuclide Therapy" (Volume 2) -- Export Date: 1 June 2023 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Lisa Bodei
    205 Bodei
  2. Vetri Sudar Jayaprakasam
    25 Jayaprakasam
Related MSK Work